According to Dr. Scott Gottlieb, the BA.2 subvariant of omicron is unlikely to trigger a "national wave" in the United States.

• According to Dr. Scott Gottlieb, the U.S. will likely avoid a "national wave" of infection this spring due to the more contagious omicron BA.2 subvariant.
• The former FDA head stated on CNBC on Tuesday that he believes we are deeper into the situation than we realize.
• In some parts of the country, particularly the Northeast, Gottlieb believes that cases are being underreported "dramatically."

On Tuesday, Dr. Scott Gottlieb informed CNBC that he believes the U.S. will avoid a "national wave" of infection this spring due to the more contagious omicron BA.2 subvariant.

The former Food and Drug Administration commissioner stated on "Squawk Box" that he believes cases are being "dramatically" underreported in certain regions of the country. With the increased use of at-home testing, he estimates that in the Northeast, only one in seven or one in eight infections are being officially reported.

Gottlieb stated that we may be deeper into the current situation than we realize, as seen in the rapid decline of cases in Germany and the U.K., which have reached their peak due to the BA.2 variant.

The Centers for Disease Control and Prevention reports that BA.2 is currently the dominant version of Covid in the U.S. Some experts predict that it may replace the earlier version of omicron, which caused a surge in cases and hospitalizations late last year and into 2022, within the next two weeks.

The number of Covid infections and hospitalizations has decreased by more than 90% since their peak during the omicron wave in January.

"According to Gottlieb, who served as FDA head under the Trump administration and is now on the board of a Covid vaccine company, it is unlikely that a national wave of infection will occur from BA.2. Instead, he predicts that the infection will be concentrated in the Northeast and possibly Florida. By the time it begins to spread nationally, it will be during the summer, providing a seasonal barrier."

Gottlieb stated that the picture may change in the fall due to a few reasons. If the BA.2 variant remains dominant in certain areas, it may spread as people's immunity decreases, they get farther from their vaccination and prior infection from omicron.

Dr. Scott Gottlieb is a CNBC contributor and serves on the boards of Pfizer, Tempus, Aetion, and biotech company. He also co-chairs the "Healthy Sail Panel" of ' and '.